EPMC Pharma is committed to bringing the best adapted treatments to the European market for neonatal children, whether as part of a consortium, under our own commercial initiative or with other pharmaceutical or biotech companies.

With several medicines in the pipeline, our first in-line product is ‘Sucrose 24%’, an aqueous sterile oral solution used as a complement to medicines and other treatments for pain in the neonate.


Do you need more information?

Feel free to use our information request form.